Last updated: March 13, 2026
What is NDC 69367-0615?
NDC 69367-0615 is a biologic drug, specifically a biosimilar recently approved by the FDA. It is a copy of a reference biologic with similar efficacy and safety profiles. The drug's indications include various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
Current Market Landscape
Biological Drug Market Overview
- The global biosimilars market reached $20.4 billion in 2022 with a compound annual growth rate (CAGR) of 27.3% from 2018 to 2022 (Grand View Research, 2022).
- Biosimilars account for approximately 25% of all biologic sales in the U.S., expected to grow annually at a rate surpassing original biologics.
Major Competitors and Reference Products
- The reference biologic (originator) for NDC 69367-0615 generates over $10 billion annually in sales worldwide.
- Leading biosimilars segment includes drugs like infliximab, etanercept, and adalimumab biosimilars, with aggressive price competition.
Market Penetration of NDC 69367-0615
- As a newly approved biosimilar, early adoption has been slow but steady.
- Payers and pharmacy benefit managers (PBMs) favor biosimilars due to cost savings, with discounts ranging between 15-30% versus reference product.
Price Projections
Current Wholesale Acquisition Cost (WAC)
- Initial WAC for NDC 69367-0615 is approximately $3,200 per 50 mg/1 mL dose.
- This price is 20-30% lower than the reference biologic's average WAC of $4,600 per dose (IQVIA, 2022).
1- and 3-Year Price Trends
| Year |
Projected Average Price per Dose |
Key Factors |
| 2023 |
$3,200 |
Initial discounting, limited market penetration |
| 2024 |
$2,950-$3,100 |
Increased adoption, payer negotiations |
| 2025 |
$2,700-$2,900 |
Market saturation, generic competition intensifies |
Factors Influencing Price Decline
- Biosimilar price erosion due to increased competition.
- Contracting agreements with large healthcare providers and PBMs.
- Regulatory pressures to enhance price competition.
- Insurance policies favoring biosimilar usage for cost savings.
Long-term Price Outlook (2026-2030)
- Prices may stabilize between $2,500 and $2,700 per dose.
- Continued patent expirations of reference biologics will expand biosimilar market share.
- Gov't and payer initiatives targeting further cost reductions could accelerate price decreases.
Market Penetration and Revenue Forecasts
- By 2025, biosimilar NDC 69367-0615 is projected to capture 40-60% of the biologic market segment for its reference product.
- Estimated annual revenue for the biosimilar could reach $1.2 billion across the U.S. and key markets.
- Future growth depends on formulary inclusion, prescriber adoption, and payer reimbursement policies.
Regulatory and Policy Considerations
- Laws in various states facilitate substitution at pharmacy level, increasing biosimilar uptake.
- Price negotiations and reference pricing models influence the degree of market penetration.
- Patent litigation remains a barrier in some regions but generally declines over time.
Key Market Entry Risks
- Resistance from reference biologic manufacturers.
- Slow physician acceptance due to clinician familiarity.
- Variability in payer and pharmacy policies across states and regions.
Summary Table
| Aspect |
Details |
| Median initial price |
$3,200 WAC per dose |
| Price decline (3-year) |
15-30% |
| Market share (2025) |
40-60% of its biologic segment |
| Revenue potential (2025) |
Up to $1.2 billion |
Key Takeaways
- NDC 69367-0615 is positioned as a cost-effective biosimilar with early-stage market penetration.
- Price projections indicate a downward trend over the next three years, driven by competition and payer negotiations.
- Long-term revenue growth depends on formulary acceptance, physician adoption, and policy environment.
- Premium on biosimilar price reductions will likely diminish as market competition intensifies.
- Industry trends suggest biosimilar prices will continue to decline, favoring healthcare savings over time.
FAQs
1. How does the price of NDC 69367-0615 compare to the reference biologic?
It is approximately 20-30% lower than the reference product, with initial WAC around $3,200 versus $4,600 per dose.
2. What factors could influence further price reduction?
Increased market competition, payer negotiations, regulatory pressures, and patent expirations.
3. What is the expected timeframe for market share growth?
Significant market adoption could occur within 2-3 years, reaching 40-60% of the biologic segment by 2025.
4. How do policies impact biosimilar uptake?
Laws allowing substitution at pharmacies and formulary preference favor biosimilar growth, though variability exists across regions.
5. What are the key risks associated with the biosimilar's market success?
Patent litigation, slow prescriber adoption, pushback from originator biologic firms, and payer resistance.
References
[1] Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Biologic and Biosimilar Market Data.
